Prognosis Worsens Once Patients Exhaust BTKi and BCL2i in CLL Most patients with CLL who discontinued BTK inhibitors and later received BCL2i achieved early responses but poor long-term outcomes.

Patients with chronic lymphocytic leukemia (#CLL) who discontinued covalent #BTKi and later required #BCL2i therapy faced diminishing clinical benefit, underscoring a pressing therapeutic gap.

Read here: https://bit.ly/3YkhbQn

#RareDisease #ChronicLymphocyticLeukemia #MedSky